Cart (0 Items)
Your cart is currently empty.
View Products
| Size | 100ug |
|---|---|
| Brand | Arovia |
| Product type | Recombinant Proteins |
| Product name | Recombinant Human ITPA, N-His |
|---|---|
| Origin species | Human |
| Expression system | Prokaryotic expression |
| Molecular weight | 22.05 kDa |
| Buffer | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| Form | Liquid |
| Delivery condition | Dry Ice |
| Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
| Brand | Arovia |
| Host species | Escherichia coli (E.coli) |
| Fragment Type | Ala3-Arg180 |
| Aliases /Synonyms | C20orf37, Inosine triphosphate pyrophosphatase, Nucleoside-triphosphate diphosphatase, Nucleoside-triphosphate pyrophosphatase, Non-canonical purine NTP pyrophosphatase, ITPA, Inosine triphosphatase, ITPase, Putative oncogene protein hlc14-06-p, Non-standard purine NTP pyrophosphatase, NTPase |
| Reference | ARO-P12808 |
| Note | For research use only. |
Recombinant Human ITPA (Inosine Triphosphatase A) is a protein that plays a crucial role in maintaining the balance of nucleotide pools in human cells. It is a highly conserved enzyme that is found in all living organisms and is essential for maintaining genomic stability. In this article, we will delve into the structure, activity, and various applications of Recombinant Human ITPA.
The human ITPA gene is located on chromosome 20 and consists of 9 exons that encode a protein of 199 amino acids. The protein is composed of two domains – a catalytic domain and a regulatory domain. The catalytic domain contains the active site of the enzyme, which is responsible for the hydrolysis of inosine triphosphate (ITP) to inosine monophosphate (IMP). The regulatory domain, on the other hand, is involved in the binding of other nucleotides and plays a role in regulating the enzyme’s activity.
Recombinant Human ITPA is produced through genetic engineering techniques, where the ITPA gene is cloned into an expression vector and then expressed in a suitable host cell. This results in a highly pure and functional protein that can be used for various applications.
The primary function of Recombinant Human ITPA is to prevent the accumulation of ITP, which is a non-canonical nucleotide that can be mistakenly incorporated into DNA during replication. This can lead to DNA damage and mutations, which can ultimately result in diseases such as cancer. By hydrolyzing ITP to IMP, Recombinant Human ITPA prevents its incorporation into DNA and maintains the integrity of the genome.
Aside from its role in nucleotide pool balance, Recombinant Human ITPA also plays a crucial role in the metabolism of purine nucleotides. It is involved in the conversion of ITP to IMP, which can then be further metabolized to produce ATP, an essential energy source for cellular processes.
The unique properties of Recombinant Human ITPA make it a valuable tool for various scientific and medical applications. Here are some of its important applications:
Recombinant Human ITPA can be used in the production of other recombinant proteins. Its ability to prevent the accumulation of ITP can be beneficial in maintaining the quality and stability of recombinant proteins, which are often produced in high quantities in host cells.
ITPA deficiency is a rare genetic disorder that results in the accumulation of ITP in the body. This can lead to neurological symptoms and an increased risk of developing certain cancers. Recombinant Human ITPA can be used as a diagnostic tool to detect ITPA deficiency and monitor its progression in affected individuals.
Given its crucial role in maintaining genomic stability and its involvement in purine nucleotide metabolism, Recombinant Human ITPA has emerged as a potential target for drug development. Inhibitors of this enzyme can be used to selectively kill cancer cells that have a high demand for purine nucleotides, making it a promising target for cancer treatment.
Recombinant Human ITPA has been identified as a potential antigen for vaccine development. Antibodies against this protein have been found in individuals infected with certain viruses, indicating its potential as a target for vaccine development against these viruses.
Send us a message from the form below
Reviews
There are no reviews yet.